15 / 1851
Molecular evolution of resistance to treatment:
Acquired during therapy?
As a result of continuing mutagenesis?
Already present in a clonal subpopulation within the tumours
prior
to the initiation of therapy?
Is resistance therefore a fait accompli—the time to recurrence is
simply the interval required for the subclone to repopulate the
lesion.?
Is the short time interval of recurrence due to the rapid expansion
of the resistant subclone immediately following treatment
initiation?
Required:
Combination therapies targeting at least two different “processes” or
“pathways”.
Relevant Questions::